These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 8781149)

  • 1. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients.
    Strauss LG
    Eur J Nucl Med; 1996 Oct; 23(10):1409-15. PubMed ID: 8781149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation.
    Stollfuss JC; Glatting G; Friess H; Kocher F; Berger HG; Reske SN
    Radiology; 1995 May; 195(2):339-44. PubMed ID: 7724750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of low-dose dobutamine-gradient-echo magnetic resonance imaging and positron emission tomography with [18F]fluorodeoxyglucose in patients with chronic coronary artery disease. A functional and morphological approach to the detection of residual myocardial viability.
    Baer FM; Voth E; Schneider CA; Theissen P; Schicha H; Sechtem U
    Circulation; 1995 Feb; 91(4):1006-15. PubMed ID: 7850935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D-glucose.
    Hoh CK; Hawkins RA; Glaspy JA; Dahlbom M; Tse NY; Hoffman EJ; Schiepers C; Choi Y; Rege S; Nitzsche E
    J Comput Assist Tomogr; 1993; 17(4):582-9. PubMed ID: 8331230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET).
    Duhaylongsod FG; Lowe VJ; Patz EF; Vaughn AL; Coleman RE; Wolfe WG
    J Thorac Cardiovasc Surg; 1995 Jul; 110(1):130-9; discussion 139-40. PubMed ID: 7609536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose.
    Rigo P; Paulus P; Kaschten BJ; Hustinx R; Bury T; Jerusalem G; Benoit T; Foidart-Willems J
    Eur J Nucl Med; 1996 Dec; 23(12):1641-74. PubMed ID: 8929320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiating benign from malignant lung lesions using "quantitative" parameters of FDG PET images.
    Hübner KF; Buonocore E; Gould HR; Thie J; Smith GT; Stephens S; Dickey J
    Clin Nucl Med; 1996 Dec; 21(12):941-9. PubMed ID: 8957608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDG-PET evaluation of indeterminate pancreatic masses.
    Ho CL; Dehdashti F; Griffeth LK; Buse PE; Balfe DM; Siegel BA
    J Comput Assist Tomogr; 1996; 20(3):363-9. PubMed ID: 8626891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does fluorine-18 fluorodeoxyglucose metabolic imaging of tumours benefit oncology?
    Brock CS; Meikle SR; Price P
    Eur J Nucl Med; 1997 Jun; 24(6):691-705. PubMed ID: 9169580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of malignancies with SPECT versus PET, with 2-[fluorine-18]fluoro-2-deoxy-D-glucose.
    Martin WH; Delbeke D; Patton JA; Sandler MP
    Radiology; 1996 Jan; 198(1):225-31. PubMed ID: 8539384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorine-18-FDG PET in Paget's disease of bone.
    Cook GJ; Maisey MN; Fogelman I
    J Nucl Med; 1997 Sep; 38(9):1495-7. PubMed ID: 9293817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation.
    Cook GJ; Fogelman I; Maisey MN
    Semin Nucl Med; 1996 Oct; 26(4):308-14. PubMed ID: 8916319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Staging of non-small-cell lung cancer by whole-body fluorine-18 deoxyglucose positron emission tomography.
    Bury T; Dowlati A; Paulus P; Hustinx R; Radermecker M; Rigo P
    Eur J Nucl Med; 1996 Feb; 23(2):204-6. PubMed ID: 8925857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positron emission tomography in oncology.
    Leskinen-Kallio S
    Clin Physiol; 1994 May; 14(3):329-35. PubMed ID: 8026150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorodeoxyglucose positron emission tomography in pancreatic cancer: an unsolved problem.
    Kato T; Fukatsu H; Ito K; Tadokoro M; Ota T; Ikeda M; Isomura T; Ito S; Nishino M; Ishigaki T
    Eur J Nucl Med; 1995 Jan; 22(1):32-9. PubMed ID: 7698152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Results of positron emission tomography with fluorine-18 labeled fluorodeoxyglucose in differential diagnosis and staging of pancreatic carcinoma].
    Bares R; Dohmen BM; Cremerius U; Fass J; Teusch M; Büll U
    Radiologe; 1996 May; 36(5):435-40. PubMed ID: 8778929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PET imaging of primary mediastinal tumours.
    Kubota K; Yamada S; Kondo T; Yamada K; Fukuda H; Fujiwara T; Ito M; Ido T
    Br J Cancer; 1996 Apr; 73(7):882-6. PubMed ID: 8611400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDG-PET for the evaluation of tumor viability after anticancer therapy.
    Okada J; Oonishi H; Yoshikawa K; Imaseki K; Uno K; Itami J; Arimizu N
    Ann Nucl Med; 1994 May; 8(2):109-13. PubMed ID: 8074956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of pleural diseases with FDG-PET imaging: preliminary report.
    Bury T; Paulus P; Dowlati A; Corhay JL; Rigo P; Radermecker MF
    Thorax; 1997 Feb; 52(2):187-9. PubMed ID: 9059484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.